-
Uncategorized3 days ago
Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset
Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.
-
Uncategorized3 days agoSTAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
-
Uncategorized3 days ago
Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
-
Uncategorized3 days agoMajor readouts from the annual diabetes conference
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Remember when the streets were covered...
-
Uncategorized4 days agoSTAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes...
-
Uncategorized4 days ago
ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset
Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as...
-
Uncategorized4 days agoIMU Biosciences raises $53m to expand disease platform
IMU Biosciences has raised $53 million in a Series A financing round, pledging to use the funds to change understanding, diagnosis and treatment of disease. The...
-
Uncategorized4 days ago
Innovation alone is no longer enough in biopharma
In biopharma, the next edge may come from the systems that turn discovery into scale. Read More
-
Uncategorized4 days agoOpinion: American horses are obese, too
The horses in America are getting fat. They are trying to tell us something. Fifty-one percent of mature light-breed horses in the United States are obese...
-
Uncategorized4 days ago
Busy FDA gives rare disease sector complementary pathways, unanswered questions
The FDA has expanded the regulatory toolkit during President Donald Trump’s second term, adding new mechanisms for rare diseases while putting the Biden-era platform technology designation...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
